Urinary and erectile dysfunction in Multiple System Atrophy (MSA)

Neurourology and Urodynamics

Volumn 27, Issue 1, 2008, Pages 22-27

  Papatsoris, A G ^a   Papapetropoulos, S ^b   Singer, C ^b   Deliveliotis, C ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Erectile dysfunction; Multiple system atrophy; Review; Treatment algorithm; Urinary dysfunction

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; APOMORPHINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; OXYBUTYNIN; PHOSPHODIESTERASE V INHIBITOR; PRAZOSIN; PROPIVERINE; SILDENAFIL; TADALAFIL; TAMSULOSIN; TOLTERODINE; VARDENAFIL;

ALGORITHM; AUTONOMIC DYSFUNCTION; BLADDER CATHETERIZATION; CEREBELLUM DISEASE; CLINICAL ASSESSMENT; DEGENERATIVE DISEASE; DETRUSOR DYSSYNERGIA; DISEASE ASSOCIATION; ERECTILE DYSFUNCTION; HUMAN; INTERMITTENT CATHETERIZATION; MORBIDITY; MORTALITY; OVERACTIVE BLADDER; PARKINSONISM; PENIS ERECTION; PERIPHERAL NEUROPATHY; PHENOTYPE; POSTVOID RESIDUAL URINE VOLUME; PROSTATE HYPERTROPHY; PYRAMIDAL SIGN; REVIEW; SHY DRAGER SYNDROME; SIDE EFFECT; SPHINCTEROTOMY; TRANSURETHRAL RESECTION; URINARY DYSFUNCTION; URINARY TRACT INFECTION; UROGENITAL TRACT DISEASE;

ERECTILE DYSFUNCTION; HUMANS; MALE; MULTIPLE SYSTEM ATROPHY; PHENOTYPE; URINARY TRACT; URINARY TRACT INFECTIONS; URINATION DISORDERS;

EID: 37849004924     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20461     Document Type: Review

References (48)

1. Schrag A, Geser F, Stampfer-Kountchev M, et al. Health-related quality of life in multiple system atrophy. Mov Disord 2006;21:809-15.
2. Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy: An analysis of 230 Japanese patients. Brain 2002;125: 1070-83.
3. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969;32:28-34.
4. Bower JH, Maraganore DM, McDonnell SK, et al. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997;49:1284-8.
5. Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: A cross-sectional study. Lancet 1999;354:1771-5.
6. Jamora RD, Gupta A, Tan AK, et al. Clinical characteristics of patients with multiple system atrophy in Singapore. Ann Acad Med Singapore 2005;34: 553-7.
7. Dickson DW, Lin W, Liu WK, et al. Multiple system atrophy: A sporadic synucleinopathy. Brain Pathol 1999;9:721-32.
8. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998;74:189-92.
9. Wenning GK, Ben-Shlomo Y, Hughes A, et al. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;68:434-40.
10. Beck RO, Betts CD, Fowler CJ. Genitourinary dysfunction in multiple system atrophy: Clinical features and treatment in 62 cases. J Urol 1994;151: 1336-41.
11. Ko T, Sakakibara R, Yasuda K, et al. Incomplete emptying and urinary retention in multiple-system atrophy: When does it occur and how do we manage it? Mov Disord 2006;21:816-23.
12. Papapetropoulos S, Tuchman A, Laufer D, et al. Causes of death in Multiple System Atrophy. J Neurol Neurosurg Psychiatry 2007;78:327-9.
13. Geser F, Seppi K, Stampfer-Kountchev M, et al. The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm 2005;112:1677-86.
14. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the standardisation subcommittee of the International Continence Society. Neurol Urodyn 2002;21: 167-78.
15. Apostolidis AN, Fowler CJ. Evaluation and treatment of autonomic disorders of the urogenital system. Semin Neurol 2003;23:443-52.
16. Papatsoris AG, Gekas A. Which is the association between erectile dysfunction and lower urinary tract symptoms? Andrologia 2004;36:402-3.
17. Winge K, Skau AM, Stimpel H, et al. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol Urodyn 2006;25:116-22.
18. Colosimo C, Pezzella FR. The symptomatic treatment of multiple system atrophy. Eur J Neurol 2002;9:195-9.
19. Papatsoris AG, Deliveliotis C, Singer C, et al. Erectile dysfunction in Parkinson's disease. Urology 2006;67:447-51.
20. Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: Mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21:737-45.
21. Wenning GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with post-mortem confirmed parkinsonian syndromes: A clinicopathological study. J Neurol Neurosurg Psychiatry 1999;67:620-3.
22. Blok BF, Holstege G. The central control of micturition and continence: Implications for urology. BJU Int 1999;83:1-6.
23. Athwal BS, Berkley KJ, Hussain I, et al. Brain responses to changes in bladder volume and urge to void in healthy men. Brain 2001;124:369-77.
24. Blok BF, Willemsen AT, Holstege G. A PET study on brain control of micturition in humans. Brain 1997;120:111-21.
25. Blok BF, Holstege G. The central nervous system control of micturition in cats and humans. Behav Brain Res 1998;92:119-25.
26. Burn DJ, Jaros E. Multiple system atrophy: Cellular and molecular pathology. Mol Pathol 2001;54:419-26.
27. Sakakibara R, Hattori T, Uchiyama T, et al. Urinary dysfunction and orthostatic hypotension in multiple system atrophy: Which is the more common and earlier manifestation? J Neurol Neurosurg Psychiatry 2000;68: 65-9.
28. Benarroch EE, Schmeichel AM, Sandroni P, et al. Differential involvement of hypothalamic vasopressin neurons in multiple system atrophy. Brain 2006; 129:2688-96.
29. van Dijken H, Dijk J, Voom P, et al. Localization of dopamine D2 receptor in rat spinal cord identified with immunocytochemistry and in situ hybridization. Eur J Neurosci 1996;8:621-8.
30. Hussain IF, Brady CM, Swinn MJ, et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001;71:371-4.
31. Kirchhof K, Apostolidis AN, Mathias CJ, et al. Erectile and urinary dysfunction may be the presenting features in patients with multiple system atrophy: A retrospective study. Int J Impot Res 2003;15:293-8.
32. Basson R. Sexuality and parkinson's disease. Parkinsonism and Relat Disord 1996;2:177-85.
33. Kirby R, Fowler C, Gosling J, et al. Urethro-vesical dysfunction in progressive autonomic failure with multiple system atrophy. J Neurol Neurosurg Psychiatry 1986;49:554-62.
34. Salinas JM, Berger Y, De La Rocha RE, et al. Urological evaluation in the Shy Drager syndrome. J Urol 1986;135:741-3.
35. Sakakibara R, Hattori T, Tojo M, et al. Micturitional disturbance in multiple system atrophy. Jpn J Psychiatry Neurol 1993;47:591-8.
36. Sakakibara R, Hattori T, Uchiyama T, et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst 2000;79:191-5.
37. Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time, sphincter EMG, and rectoanal videomanometry in multiple system atrophy Mov Disord 2004;19:924-9.
38. Wenning GK, Ben-Shlomo Y, et al. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994;117: 835-45.
39. Oertel WH, Wachter T, Quinn NP, et al. Reduced genital sensitivity in female patients with multiple system atrophy of parkinsonian type. Mov Disord 2003;18:430-2.
40. Araki I, Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J Neurol Neurosurg Psychiatry 2000;68:429-33.
41. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (HEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
42. Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 1998;8:359-62.
43. Colosimo C, Tiple D, Wenning GK. Management of multiple system atrophy: State of the art. J Neural Transm 2005;112:1695-704.
44. Sethia KK, Selkon JB, Berry AR, et al. Prospective randomized controlled trial of urethral versus suprapubic catheterization. Br J Surg 1987;74:624-5.
45. Carson CC. PDE5 inhibitors: Are there differences? Can J Urol 2006;13: 34-9.
46. O'Sullivan JD, Hughes AJ. Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 1998;13:536-9.
47. O'Sullivan JD. Apomorphine as an alternative to sildenafil in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;72:681.
48. Maclennan KM, Boshier A, Wilton LV, et al. Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction. BJU Int 2006;98:125-31.